** Shares of eye-drug maker Harrow Inc HROW.O fall 24.7% to $39 premarket
** Co's Q3 revenue rose 43.8% to $49.3 mln, missing estimates of $52.8 mln as per data compiled by LSEG
** HROW's adj. earnings before interest, tax, depreciation and amortization at $8.8 mln vs estimates of $11.7 mln
** Reported qtrly. loss of 12 cents per share
** Alongside 44% Y‑o‑Y revenue growth, co achieved a modest sequential revenue increase, despite Q3's traditional summer seasonality and operational bumps that pushed some Q3 revenue into Q4 - Mark L. Baum, CEO
** Avg rating of 4 brokerages is a "buy"; median PT is $60 - LSEG data
** As of last close, stock has more than quadrupled YTD
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。